ライフサイエンスコーパス: juvenile myelomonocytic leukemia

1 in children with CBL syndrome and transient juvenile myelomonocytic leukemia.

2 cure a relevant proportion of children with juvenile myelomonocytic leukemia.

3 2AF35, and SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia.

4 A 3-year-old boy was treated for juvenile myelomonocytic leukemia.

5 alignancies, including an increased risk for juvenile myelomonocytic leukemia.

6 Juvenile myelomonocytic leukemia, acute myeloid leukemia

7 occurs in specific human cancers, including juvenile myelomonocytic leukemia, an aggressive myelopro

8 some mutations are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to ope

9 suppressor gene is frequently inactivated in juvenile myelomonocytic leukemia, and Nf1 mutant mice mo

10 s associated with marked thrombocytosis, and juvenile myelomonocytic leukemia, are clonal hematologic

11 We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child wi

12 y contributing to the pathogenesis of NS and juvenile myelomonocytic leukemia caused by PTPN11 gain-o

13 e retrospectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unr

14 Juvenile myelomonocytic leukemia is an aggressive and fr

15 Juvenile myelomonocytic leukemia is an aggressive myelop

16 ularly juvenile chronic myelogenous leukemia/juvenile myelomonocytic leukemia (JCML/JMML).

17 RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloi

18 boratory features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myel

19 a (AML), acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML) and LEOPARD synd

20 Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irr

21 human hematopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymph

22 Overactive RAS signaling is prevalent in juvenile myelomonocytic leukemia (JMML) and the myelopro

23 Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplas

24 r (GM-CSF) hypersensitivity is a hallmark of juvenile myelomonocytic leukemia (JMML) but has not been

25 re that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mu

26 Juvenile myelomonocytic leukemia (JMML) is a disease tha

27 Juvenile myelomonocytic leukemia (JMML) is a lethal dise

28 Juvenile myelomonocytic leukemia (JMML) is a myeloprolif

29 Juvenile myelomonocytic leukemia (JMML) is a pediatric m

30 Juvenile myelomonocytic leukemia (JMML) is a pediatric m

31 Juvenile myelomonocytic leukemia (JMML) is a rare and ag

32 Juvenile myelomonocytic leukemia (JMML) is a rare clonal

33 Juvenile myelomonocytic leukemia (JMML) is a rare pediat

34 Juvenile myelomonocytic leukemia (JMML) is a typically a

35 Juvenile myelomonocytic leukemia (JMML) is a unique, agg

36 Juvenile myelomonocytic leukemia (JMML) is an aggressive

37 Juvenile myelomonocytic leukemia (JMML) is an aggressive

38 Juvenile myelomonocytic leukemia (JMML) is an aggressive

39 Juvenile myelomonocytic leukemia (JMML) is an aggressive

40 Juvenile myelomonocytic leukemia (JMML) is an early chil

41 Juvenile myelomonocytic leukemia (JMML) is characterized

42 Juvenile myelomonocytic leukemia (JMML) is characterized

43 f mononuclear cells from five of seven (71%) juvenile myelomonocytic leukemia (JMML) patients and fro

44 dren with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uni

45 of validating the molecular underpinnings of juvenile myelomonocytic leukemia (JMML) with the generat

46 way is known to underlie the pathogenesis of juvenile myelomonocytic leukemia (JMML), a fatal childho

47 redisposes individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myelopr

48 osphatase PTPN11 (SHP-2) are associated with juvenile myelomonocytic leukemia (JMML), a myeloprolifer

49 fibromatosis type 1 (NF1) are predisposed to juvenile myelomonocytic leukemia (JMML), an aggressive m

50 ype myelodysplastic syndrome (A-MDS), 60 had juvenile myelomonocytic leukemia (JMML), and 6 infants w

51 oodwin et al investigate the pathogenesis of juvenile myelomonocytic leukemia (JMML), demonstrating t

52 id in acute promyelocytic leukemia (APL) and juvenile myelomonocytic leukemia (JMML), we evaluated UA

53 in childhood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which is a myel

54 yeloproliferative disorders (MPD), including juvenile myelomonocytic leukemia (JMML).

55 ) and sAML, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML).

56 that is associated with an elevated risk of juvenile myelomonocytic leukemia (JMML).

57 n 35% of patients with de novo, nonsyndromic juvenile myelomonocytic leukemia (JMML).

58 spectrum of hematologic disorders, including juvenile myelomonocytic leukemia (JMML).

59 n for p21(ras), is frequently inactivated in juvenile myelomonocytic leukemia (JMML).

60 Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML).

61 sposed to myeloid malignancies, particularly juvenile myelomonocytic leukemia (JMML).

62 signaling and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs).

63 11 mutations occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrom

64 In 1 juvenile myelomonocytic leukemia patient, the SRSF2 muta

65 Juvenile myelomonocytic leukemia patients without PTPN11

66 in human chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia samples.

67 identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized